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Abstract 
 
Testing for the presence of antibody to hepatitis C virus (anti-HCV) is recommended for initially 
identifying persons with HCV infection. According to the CDC guidelines it is appropriate to use a 
signal-to-cut-off value (S/CO) to limit the number of samples that needs supplemental testing. 
Moreover, the use of quantitative PCR assays for HCV RNA testing is fundamental for the 
assessment of chronic hepatitis C. The purpose of this study is to determine a specific value for a 
serological test for anti-HCV with a Positive Predictive Value (PPV) of 95% on positive HCV 
Immunoblot, and also determine a cut-off value for performing a clinically relevant HCV PCR. Were 
observed 415 individuals identified de novo as anti-HCV reactive, between 2009 and 2011. We 
estimate that a S/CO of 6.0 has a PPV of 99.83% being positive Immunoblot assay and that 99.49% 
of the samples with a S/CO ≤6.0 will have no detectable virus on PCR. Based on these results we 
propose a new algorithm for evaluation persons identified de novo as anti-HCV reactive: 
Immunoblot assay needs to be performed only for samples with a S/CO ≤6.0 and HCV PCR will be 
performed for persons with a S/CO >6.0. Using these criteria it would be possible to save € 
9,000/year with acceptable clinical accuracy. This algorithm does not apply to rare cases of 
suspected acute HCV infection or suspicion of HCV infection in immunocompromised patients; for 
these cases we maintain the current approach of NAT testing for laboratory diagnosis of HCV 
infection. 
 
Keywords: HCV, Inno-lia, PCR, Immunoblot. 
 
 
Introduction 
 
Diagnosis of HCV infection is based on 
detection of antibodies to hepatitis C (anti-
HCV) antibodies by immunoassay and 
detection of HCV RNA by a sensitive 
molecular method (lower limit of detection 
<50 IU/ml), ideally a real-time PCR assay. 
 
 
An appropriate use of the available 
laboratory assays is crucial for an accurate 
and efficient diagnosis of HCV infection 
because there are important medical and 
social implications for persons designated as 
having HCV infection. 
 
Testing for the presence of antibodies to 
hepatitis C virus (anti-HCV) is recommended 
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for initially identifying persons with HCV 
infection and should include the use of an 
anti-HCV screening test and a more specific 
supplemental assay. According to CDC 
guidelines it is appropriate to use a signal-to-
cut-off value (S/CO) to limit the number of 
samples that needs supplemental testing. 
Moreover, the quantitative test (viral load) of 
polymerase chain reaction for HCV RNA (PCR 
HCV) is fundamental for the assessment of 
chronic hepatitis C, and due to its high cost it 
must be used judiciously. 
 
With the purpose of reducing costs by 
eliminating unnecessary lab tests, the 
authors intended to determine a specific 
value of anti-HCV ratio (S/CO) in screening 
tests that can predict with a Positive 
Predictive Value (PPV) of 95% a true-positive 
result for HCV, and also determine a cut-off 
value for performing a clinically relevant PCR 
HCV. 
 
Materials and Methods 
 
The analysis reported here is based on files 
from our laboratory, at Centro Hospitalar São 
João, containing information about patients, 
results of HCV serologic screening and 
supplemental test results. 
 
It includes all patients identified de novo as 
anti-HCV reactive, from January 1, 2009, 
through December 31, 2011. 
 
In our lab, testing for HCV infection is 
performed for clinical diagnosis of patients 
with signs or symptoms of liver disease and 
for screening asymptomatic persons to 
identify HCV-infected persons who should 
receive counselling and medical evaluation. 
 
Anti-HCV testing includes initial screening 
with Architect Anti-HCV assay on the 
Architect i2000SR system (Abbott 
Laboratories, Abbott Park, IL). This assay is a 
two-step immunoassay for the qualitative 
detection of hepatitis C antibody (anti-HCV) 
in human serum or plasma using 
chemiluminescent assay (CMIA) technology. 
 
 The resulting chemiluminescent reaction is 
measured as relative light units (RLUs). A 
relationship exists between the amount of 
anti-HCV in the sample and the RLUs 
detected by the Architect i optical system. For 
each sample the Architect Anti-HCV assay 
protocol calculates a result based on the ratio 
of the sample RLU (S) to the cutoff RLU (CO). 
 
Samples showing repeat reactive results 
(S/CO ≥0.9) are tested with the Immunoblot 
assay INNO-LIA™ HCV Score (Innogenetics) 
on Auto-LiPA equipment. This assay utilizes 
well-defined antigens derived from HCV 
immunodominant proteins from the core 
region, the E2 hypervariable region (HVR), 
the NS3 helicase region and the NS4A, NS4B 
and NS5A regions. The antigens used are 
either recombinant proteins or synthetic 
peptides, highly purified, and fixed on a nylon 
membrane. In addition the strip includes four 
control lines: a streptavidin control line, 
weak and medium positive control lines 
(human IgG), and a strong positive control 
line (anti-human IgG) which is also the 
sample addition control line. The 
interpretation of results is performed 
according to the manufacturer's instructions. 
 
A negative Immunoblot result is interpreted 
as anti-HCV negative. Nucleic acid testing 
(NAT) is not performed. 
 
NAT testing, for the detection of HCV RNA, is 
carried out, in the cases of INNO-LIA positive 
or indeterminate. 
 
In both cases, after patient’s physician 
request, the detection of HCV RNA is 
performed with a new fresh specimen, using 
a real time PCR assay (PCR COBAS 
Ampliprep/COBAS TAqMan-HCV 
Quantitative Test v2.0-Roche©), with a 
diagnostic sensivity and linearity from ≥15 
UI/mL. 
 
Statistical study was based on analysis of the 
one-tailed distribution curves, aiming to find 
a ratio (S/CO) where the area under the 
curve was >95.00% for both parameters. 
 
Results 
 
During the three-year study period, 415 
patients were identified de novo as anti-HCV 
reactive (S/CO ≥0.9). 
 
After performing INNO-LIA test, 266 patients 
(64.1%) were classified as anti-HCV positive, 
114 patients (27.5%) as anti-HCV Negative 
and 35 patients (8.4%) as Indeterminate. 
 
None of patients classified as anti-HCV 
Negative had been tested for HCV RNA. The 
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patients classified as anti-HCV Indeterminate 
had been tested for HCV RNA and all were 
RNA PCR Not Detected. 
 
Out of 266 patients with INNO-LIA positive 
result, 149 (56%) had been tested for HCV 
RNA. 
 
For statistical purpose, INNO-LIA test results 
have been divided into two groups: Positive 
(266 patients) and Negative/Indeterminate 
(149 patients). For each group we calculate 
the average, standard deviation and standard 
error of Architect anti-HCV screening test 
result (S/CO) and the data was analyzed to 
determine a specific ratio (S/CO) that could 
predict with a PPV greater than 95% a true-
positive anti-HCV. Table 1. 
 
Table 1: Results of INNO-LIATM in 415 Samples with Anti-HCV (S/CO) ≥0, 9 
 
Also for statistical purpose, NAT test results 
belonging to 149 patients with INNO-LIA 
positive have been divided into two groups: 
RNA Detected (88) and RNA Not Detected 
(61). For each group we calculate the 
average, standard deviation and standard 
error of Architect anti-HCV screening test 
result (S/CO), and the data were analyzed to 
calculate a ratio (S/CO) below which we 
could predict (with a probability greater than 
95%) a RNA HCV Not Detected. Table 2. 
 
Table 2: Results of PCR HCV in 149 INNO-LIA Positive Samples 
 
 
In Figure 1 we can see the distribution of 
INNO-LIA and PCR HCV test results. When we 
analyze the data related to the INNO-LIA test, 
we can see that for a value (S/CO) of 5.8 (95 
percent confidence interval: 5.6 – 6.0) in the 
screening test, 99.83% of results with value 
greater than or equal to 5.8 will be INNO-LIA 
positive and 0.17% will be INNO-LIA 
Negative. Regarding to PCR HCV, we can see 
that for a value (S/CO) of 6.47 (CI 95%: 6.0 – 
6.93) in the screening test, 99.49% of results 
with value lower than or equal to 6.47 will be 
PCR HCV "Not Detected" and 0.51% will be 
PCR HCV positive. 
 
 
 
 
 
 
 INNO-LIATM Negative/Indeterminate INNO-LIATM Positive 
N 149 (115/34) 266 
Mina 1.0 1.1 
Maxa 7.3 17.6 
Averagea 2.10 (2.22/1.70) 11.49 
Standard deviationa 1.23 (1.35/0.56) 3.46 
Standard error 
(95%)a 
0.20 (0.25/0.19) 0.42 
a Ratio (S/CO) 
 PCR HCV "Not Detected" PCR HCV “Detected” 
N 61 88 
Mina 1.0 6.0 
Maxa 16.0 16.6 
Averagea 6.59 12.27 
Standard deviationa 5.08 2.21 
Standard error 
(95%)a 
1.29 0.47 
a Ratio (S/CO) 
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According to these results and to facilitate 
the creation of a laboratorial algorithm, we 
use the common value (S/CO = 6) to both 
confidence intervals of the estimated cut-offs, 
for INNO-LIATM and PCR HCV, as an overall 
cut-off, proposing the algorithm displayed in 
Figure 2. 
 
 
 
Figure 2: Laboratorial Algorithm for Guidance in Performing Analysis 
  
 
Figure 1: Amostral Distribution of INNO-LIA and PCR Results, According to the Values of (S/CO) 
Obtained from the Screening Test 
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Discussion 
 
According to the European Association for 
the Study of the Liver (EASL), the diagnosis of 
chronic hepatitis C is based on the detection 
of HCV infection (positive anti-HCV 
antibodies and HCV RNA) in a patient with 
signs of chronic hepatitis. Rarely, in 
profoundly immunosuppressed patients, 
anti-HCV antibodies are not detected and 
HCV RNA is present alone. 
 
Some studies showed that it is appropriate to 
use a signal-to-cut-off value (S/CO) to limit 
the number of samples that needs 
supplemental testing. However, given the 
existence of different equipment and 
methodologies, this value cannot be 
generalized and it is highly recommended 
that each laboratory/hospital calculate this 
value depending on the equipment and 
methodologies available to them. As a 
positive anti-HCV result may indicate past 
infection or active infection, the NAT testing 
is important to differentiate these two 
situations.  
 
With this study the authors intended to 
calculate two cut-off values (S/CO) for the 
screening test anti-HCV (Architect Abbott©): 
A value above which the assay predicts a 
positive Immunoblot result, over 95% of the 
time, and a value below which, it predicts a 
negative PCR by more than 95% of the time, 
in the study population. 
 
Using data belonging to patients identified de 
novo as anti-HCV reactive, from 2009 to 
2011, two cut-off values were obtained: 5.8 
(CI 95%: 5.6 – 6.0), indicating that results 
above or equal to 5.8 are true positives in 
Immunoblot test (with a probability greater 
than 99%) and 6.47 (CI 95%: 6.0 – 6.93), 
indicating that the results below 6.47 have 
undetectable viral load (with a probability 
greater than 99%). Using the common value 
to both confidence intervals, we defined a 
global cut-off value, to build a simple 
algorithm, in patients identified de novo, for 
the laboratory diagnosis of HCV infection. 
 
Our data shows that out of the 415 reactive 
results (≥0.9), 27.5% were classified as 
negative, 8.4% as indeterminate and 64.1% 
as positive in Immunoblot test. An 
indeterminate result indicates that the 
reading pattern was inconclusive and may 
indicate a process of seroconversion but 
usually corresponds to a false reactive, 
particularly in low-risk populations. 
 
In our study, the patients classified as anti-
HCV Indeterminate had been tested for HCV 
RNA and all were RNA PCR Not Detected. All 
PCR HCV positive cases had a prior positive 
test result in the Immunoblot assay. 
The study population included individuals 
with different prevalence of HCV infection, 
including patients with liver disease, 
haemodialysis patients and healthcare 
workers. 
 
The EASL states that the diagnosis of HCV 
infection is based on the evidence of a 
positive anti-HCV and PCR HCV, but does not 
states against the use of Immunoblotting or 
recommend any laboratorial algorithm. The 
American Association for the Study of Liver 
Diseases (AASLD) Practice Guidelines states 
that nowadays the Immunoblotting has no 
role for high S/CO ratios due to extremely 
high specificity for third generation EIA. This 
affirmation is consistent with our algorithm. 
According to the HCV Infection Testing for 
Diagnosis Flow Chart from CDC, there is no 
rule to choose between PCR HCV or 
Immunoblot when the screening test has a 
low S/CO ratio and no other test has been 
done. CDC has also published a cut-off value 
for Architect Anti-HCV screening test with a 
value of ≥ 5.0 (predictive of a true positive ≥ 
95%), but this do not take in account a cut-off 
for PCR HCV. Our algorithm suggests that we 
should use the Immunoblot assay for low 
S/CO ratios, and PCR HCV for high S/CO 
ratios. 
 
It should be noted that if we adopt the 
proposed laboratorial algorithm, a HCV RNA 
quantitative assay must always be done if a 
positive or indeterminate Immunoblot result 
is obtained, even below the proposed cut-off 
value. This is very crucial for the individuals 
with an anti-HCV positive test not only for 
HCV diagnosis but also for the evaluation of 
treatment. 
 
This algorithm does not apply to rare cases of 
suspected acute HCV infection or suspicion of 
HCV infection in immunocompromised 
patients; for these cases we maintain the 
current approach of NAT testing for 
laboratory diagnosis of HCV infection.  
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Searching for S/CO ratios among special 
populations, such as related with occult HCV 
infection, would add clinical value and 
further studies should be conducted. 
 
Conclusions 
 
The results of these study allow us to state 
that, in patients identified de novo in the anti-
HCV screening test, if the result obtained 
(S/CO) is >6.0, the probability of obtaining a 
INNO-LIATM HCV positive result is >99.83%, 
and therefore we propose that the 
Immunoblot test should be performed only 
when the S/CO of anti-HCV screening test is ≤ 
6.0. 
 
The study also allow us to suggest that if the 
anti-HCV screening test has a S/CO of ≤6.0, 
the probability of obtaining a result PCR HCV 
“Not Detected” is ≥99.49%, and therefore we 
propose that PCR HCV shall be performed 
only when the S/CO of anti-HCV screening 
test is greater than 6.0. 
 
The financial impact related with the 
implementation of this new approach was 
estimated. During the three-year study, an 
average of 138 INNO-LIATM and 50 PCR HCV 
tests were performed annually, on patients 
identified de novo. Of these, 81 INNO-LIATM 
tests had results (S/CO) of >6.0 and 13 PCR 
HCV had results (S/CO) of ≤6.0. 
 
According to the ordinance of Official Gazette 
of Portugal, the cost is set at €102.90/sample 
for the INNO-LIATM supplementary test, and 
€66.80/sample for PCR HCV, which totals 
€17,540.20/year, if the previous strategy is 
maintained. Adopting the approach proposed 
by this study, in immunocompetent 
populations, it would be possible, at best, to 
save ≈€9,203.30/year, i.e. more than a half of 
that expenditure (≈52.47%), without 
jeopardizing the quality of laboratory testing. 
 
The implementation of an appropriate 
algorithm, based on a specific value of the 
screening test to determine which test to be 
carried out subsequently, facilitates and 
enhances the laboratory diagnosis in patients 
identified de novo, allowing a substantial 
reduction in costs. 
 
Limitations of the Study 
 
There are some limitations that need to be 
acknowledged and addressed regarding the 
present study. The first limitation concerns 
the target population of this research that is 
limited to patients with different prevalence 
of HCV infection, among which were patients 
with liver disease, haemodialysis patients 
and healthcare workers. Blood donors were 
not included. Therefore we have a 
heterogeneous population, however this is 
common in a hospital-based laboratory. 
Another concern is the timing, this study only 
analyzed persons identified de novo, and 
cannot be generalized for follow-up patients.  
 
Finally, the available data is limited, since this 
is a retrospective study and there was no PCR 
available for negative Immunoblot tests. 
 
Therefore we advise that these results should 
be interpreted with caution, and it is highly 
recommended that each laboratory/hospital 
calculate the cut-off value depending on the 
equipment and methodologies available to 
them. 
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